Spinal fluid injection shows promise for breast cancer brain spread
NCT ID NCT01373710
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new way to give the drug trastuzumab (Herceptin) to women with HER2-positive breast cancer that had spread to the lining of the brain. Instead of through a vein, the drug was injected directly into the spinal fluid via a lumbar puncture or a special reservoir. The goal was to find a safe dose and see if it could control the cancer in the brain. The trial enrolled 34 participants and looked at side effects and how long the cancer stayed stable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab (Herceptin) injected into the spinal fluid
What this could lead to
If it works, this could offer a way to treat breast cancer that has spread to the lining of the brain, potentially slowing the disease and improving symptoms.
What could go wrong
This is an early-phase trial with only 34 participants, so results may not apply to everyone. The treatment involves direct spinal injections, which carries risks like infection or nerve damage, and it may not control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Grenoble
Grenoble, 38700, France
-
François Baclesse Center
Caen, Calvados, 14076, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Curie - Claudius Regaud Hospital
Paris, Île-de-France Region, 75248, France
-
Institut Univesitaire du Cancer de Toulouse
Toulouse, 31100, France
-
Institut du Cancer de Montpellier
Montpellier, 34298, France
-
Léon Bérard Center
Lyon, Rhone, 69373, France
-
Oscar Lambret Center
Lille, Nord, 59020, France
-
Pitie Salpetriere Hospital
Paris, Île-de-France Region, 75651, France
-
Rene Huguenin Hospital
Saint-Cloud, Haut de Seine, 92210, France